Yarrow Upsizes Offering to $161.8M as Underwriters Exercise Full Overallotment
YARW sits 79% above its 52-week low of $14.675.
Summary
Yarrow Bioscience finalized its underwritten offering at $161.8 million in net proceeds after underwriters exercised the full overallotment option, bringing total shares sold to 6,634,615 at $26.00 per share.
Key Events · Financing and Capital Events · YARW
-
Overallotment Fully Exercised
Underwriters exercised the 865,384-share overallotment option in full on September 11, 2026, increasing total shares sold to 6,634,615 from the base 5,769,231.
-
Net Proceeds Rise to $161.8M
Net proceeds increased to approximately $161.8 million after underwriting discounts, commissions, and estimated expenses — up from the ~$140.7 million base offering.
-
Pricing at $26.00 Per Share
Shares were sold at $26.00 each, with underwriters paying $24.44 per share; the offering closed on September 14, 2026.
-
60-Day Lock-Up Agreements
Directors and executive officers, including OrbiMed affiliates, entered 60-day lock-up agreements restricting share sales without underwriter consent.
Analysis · YARW · Life Sciences
The underwritten offering expanded to 6,634,615 shares after underwriters exercised their full 865,384-share overallotment option, lifting net proceeds to approximately $161.8 million. Priced at $26.00 per share — a modest discount to the prior close — the deal closed on September 14, 2026. The capital meaningfully extends the company's runway as it advances YB-101 through Phase 2a/2b trials, though existing shareholders absorb the dilution from the expanded share count.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, YARW was trading at $26.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $70.1M. The 52-week trading range was $14.68 to $46.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.